


omaveloxolone

Nrf2

oral, once-daily Nrf2 activator
approved to treat Friedreich's ataxia
from modification of oleanolic acid
Biogen Reata Acquisition, July 28, 2023

REATA PHARMA, TX / BIOGEN, MA




LUNA18

KRAS

oral KRAS inhibitor
Ph. I dose-escalation for metastatic solid tumors
from mRNA display library hit
J. Am. Chem. Soc., July 18, 2023

CHUGAI, YOKOHAMA, JP




AZD4747

KRAS^{G12C}

brain-penetrant KRAS^{G12C} inhibitor
initial discovery for KRAS^{G12C}-positive tumors
from structure-based drug design
J. Med. Chem., July 3, 2023

ASTRAZENECA, CAMBRIDGE, UK




AEF0117

CB1

signaling-specific CB1 inhibitor
Ph. IIb for cannabis use disorder
from rational design of pregnenolone derivatives
Nat. Med., June 8, 2023

AELIS FARMA, BORDEAUX, FR




brigimadlin

MDM2

oral MDM2-p53 PPI
Ph. II/III for DDLPS
designed from prior spirooxindoles
Cancer Discov., July 10, 2023

BOEHRINGER INGELHEIM, VIENNA, AT




JNJ-54175446

P2X7R

P2X7R antagonist
Ph. II for major depressive disorder
from prior P2X7R CNS penetrating leads
Transl. Psychiatry, July 24, 2023

JANSSEN, LA JOLLA, CA




arazasetron

H4R + 5-HT3

oral H4R + 5-HT3 antagonist
positive results in Ph. IIa for sudden sensorineural hearing loss
besylated form of (R)-azasetron
Press Release, July 5, 2023

SENSORION, MONTPELLIER, FR




JT001

NLRP3

NLRP3 inflammasome inhibitor
oral efficacy in models; related to Ph. I candidate GDC-2394
from MCC950 and opt. for lipophilic ligand efficacy
J. Pharmacol. Exp. Ther., August 1, 2023

JECURE / GENENTECH, CA




acoramidis

TTR

oral TTR stabilizer
efficacy in Ph. III in ATTR-CM
hit from HTS for TTR ligands + opt.
Press Release, July 17, 2023

BRIDGEBIO, PALO ALTO, CA



KCL-286

RARβ

oral RARβ agonist
efficacy data in Ph. I for spinal cord injury
ligand-based virtual screen + opt.
Br. J. Clin. Pharmacol., July 4, 2023

KING'S COLLEGE LONDON, LONDON, UK